Solstice Neurosciences, Inc. Release: MYOBLOC(R) (Botulinum Toxin Type B) Gains Expanded Access In First Coast Service Options’ Florida And Connecticut Medicare Programs

MALVERN, Pa., June 15 /PRNewswire/ -- Solstice Neurosciences, Inc. has received expanded access coverage for Myobloc® (Botulinum Toxin Type B) Injectable Solution for First Coast Service Options’ (FCSO) Medicare patients in Florida and Connecticut. The expanded access coverage went into effect May 8, 2006.